Journal article
Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
AJ Thompson, AJ Muir, MS Sulkowski, D Ge, J Fellay, KV Shianna, T Urban, NH Afdhal, IM Jacobson, R Esteban, F Poordad, EJ Lawitz, J McCone, ML Shiffman, GW Galler, WM Lee, R Reindollar, JW King, PY Kwo, RH Ghalib Show all
Gastroenterology | Published : 2010
Abstract
Background & Aims: We recently identified a polymorphism upstream of interleukin (IL)-28B to be associated with a 2-fold difference in sustained virologic response (SVR) rates to pegylated interferon-alfa and ribavirin therapy in a large cohort of treatment-naive, adherent patients with chronic hepatitis C virus genotype 1 (HCV-1) infection. We sought to confirm the polymorphism's clinical relevance by intention-to-treat analysis evaluating on-treatment virologic response and SVR. Methods: HCV-1 patients were genotyped as CC, CT, or TT at the polymorphic site, rs12979860. Viral kinetics and rates of rapid virologic response (RVR, week 4), complete early virologic response (week 12), and SVR ..
View full abstractGrants
Funding Acknowledgements
This study was funded by Schering-Plough Research Institute, Kenilworth, NJ; Alexander Thompson received funding support from the Duke Clinical Research Institute, the Richard B. Boebel Family Fund, the National Health and Medical Research Council of Australia, and the Gastroenterology Society of Australia and the Royal Australasian College of Physicians.r Jennifer King, PhD, provided editorial assistance in preparing the manuscript; she was funded by the Duke Clinical Research Institute, Duke University. The sponsor did not provide any funding for Dr King or have any contact with her.